Mode
Text Size
Log in / Sign up
N/A N=22 Randomized Prevention

Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Fat

Prediabetes

Enrolled (actual)
22
Serious AEs
0.0%
Results posted
Apr 2019
Primary outcome: Primary: Vascular Endothelial Function — -195.9; -6.181; -5.629 %*min

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Glucose (Other); Glucose with Whole Fat Milk (Other); Glucose with Non-fat Milk (Other)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Ohio State University
Primary completion
Apr 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Vascular Endothelial Function
-195.9; -6.181; -5.629
SECONDARY
Biomarker of Nitric Oxide Homeostasis (NOx)
-2229; -1240; -1221
SECONDARY
Glucose
6259; 4481; 3408
SECONDARY
Oxidative Stress Biomarker (Malondialdehyde; MDA)
54.9; 25.78; 31.3

Summary

Cardiovascular disease (CVD) is the leading cause of death in the United States. Short-term increases in blood sugar, or postprandial hyperglycemia (PPH), affect blood vessel function and increase the risk of CVD. Greater intakes of dairy foods have been associated with a lower risk of CVD, but whether these effects occur directly or indirectly by displacing foods in the diet that might increase CVD risk is unclear. Further controversial is the extent to which dietary fat derived from dairy foods regulate the risk of CVD. The health benefits of dairy on CVD risk are at least partly attributed to its ability to limit PPH and resulting PPH-mediated responses leading to vascular dysfunction. This provides rationale to investigate full-fat containing dairy as a dietary strategy to reduce PPH and risk for heart disease. The objective of this project is to define the extent to which full-fat dairy milk compared to non-fat dairy milk protects against PPH-induced vascular dysfunction by reducing oxidative stress responses that limit nitric oxide bioavailability to the vascular endothelium in adults with prediabetes.

Eligibility Criteria

Inclusion Criteria

  • hemoglobin A1c 5.7-6.4%
  • non-dietary supplement user
  • no medications affecting vasodilation, inflammation, or energy metabolism
  • no CVD
  • nonsmokers
  • individuals having blood pressure 3 drinks/day or >10 drinks/week
  • ≥ 7 hours/week of aerobic activity
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02482610). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search